Unknown

Dataset Information

0

Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.


ABSTRACT: Hematopoietic stem cell transplantation (HSCT) is an established treatment for multiple myeloma (MM), a plasma cell malignancy. To identify an improved pretransplant conditioning regimen, we investigated the cytotoxicity of gemcitabine (Gem) and clofarabine (Clo) combinations toward MM cell lines and patient cell samples. A strong synergism of the two nucleoside analogs, when combined at their approximate IC10 concentrations, was observed. This synergism could be partly due to the observed Gem-mediated phosphorylation and activation of deoxycytidine kinase, resulting in enhanced phosphorylation of Gem and Clo. Their cytotoxicity correlated with a robust activation of the DNA damage response pathway. [Gem+Clo] decreased the mitochondrial membrane potential with a concomitant release of proapoptotic factors into the cytoplasm and nucleus and the activation of apoptosis. Exposure of MM cells to [Gem+Clo] also decreased the level of ribosomal RNA (rRNA), which might have resulted in nucleolar stress, as reported previously, and caused a p53-dependent cell death. A reduction by approximately 50% in the cytotoxicity of Gem and Clo was observed in the presence of pifithrin ?, a p53 inhibitor. Furthermore, MM cell lines with mutant p53 exhibited greater resistance to Gem and Clo, supporting a role for the p53 protein in these cytotoxic responses. Our results provide a rationale for clinical trials incorporating [Gem+Clo] combinations as part of conditioning therapy for high-risk patients with MM undergoing HSCT.

SUBMITTER: Valdez BC 

PROVIDER: S-EPMC3769691 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.

Valdez Benigno C BC   Wang Guiyun G   Murray David D   Nieto Yago Y   Li Yang Y   Shah Jatin J   Turturro Francesco F   Wang Michael M   Weber Donna M DM   Champlin Richard E RE   Qazilbash Muzaffar H MH   Andersson Borje S BS  

Experimental hematology 20130503 8


Hematopoietic stem cell transplantation (HSCT) is an established treatment for multiple myeloma (MM), a plasma cell malignancy. To identify an improved pretransplant conditioning regimen, we investigated the cytotoxicity of gemcitabine (Gem) and clofarabine (Clo) combinations toward MM cell lines and patient cell samples. A strong synergism of the two nucleoside analogs, when combined at their approximate IC10 concentrations, was observed. This synergism could be partly due to the observed Gem-m  ...[more]

Similar Datasets

| S-EPMC3913938 | biostudies-other
| S-EPMC3942691 | biostudies-literature
| S-EPMC8489015 | biostudies-literature
| S-EPMC4394133 | biostudies-literature
| S-EPMC2360654 | biostudies-literature
| S-EPMC3766179 | biostudies-literature
2005-10-30 | GSE1862 | GEO
| S-EPMC7927863 | biostudies-literature
| S-EPMC8637561 | biostudies-literature
| S-EPMC8509545 | biostudies-literature